Immuron Limited · ASX:IMC
Immuron — Emerging Growth Conference 2025
17 slides from Immuron's conference presentation, Oct 23, 2025
Slide 1: Immuron CEO presentation to Emerging Growth Conference
Immuron CEO, Steven Lydeamore presentation to Emerging Growth Conference Melbourne, Australia, October 23, 2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the Emerging Growth Conference on Wednesday 22n
Slide 2: For personal use only
are orally active. Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits direc
Slide 3: References and forward-looking statements
Irritable bowel syndrome (IBS) is a common condition where you experience symptoms related to your digestive system. This is sometimes linked to certain foods, lifestyle habits and stress levels or mood. IBS affects around 3 out of every 10 people. Females are more likely than males to be affected.
Slide 4: Emerging Growth Conference October 2025
For personal use only EMERGING GROWTH CONFERENCE 22 OCTOBER 2025 S t e v e n Ly d e a m o r e - C E O NASDAQ: IMRN ASX: IMC
Slide 5: Safe Harbor Statement
SAFE HARBOR STATEMENT C e r t a i n s t a t e m e nt s m a d e i n t h i s p re s e nt a t i o n a re fo r wa rd - l o o k i n g s t a t e m e nt s a n d a re b a s e d o n I m m u ro n ’s c u r re nt ex p e c t a t i o n s , e s t i m a t e s a n d p ro j e c t i o n s . Wo rd s s u c h a s “a nt i
Slide 6: Executive summary
Executive summary Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Company Overview For personal use only Three commercial products: Travelan® (travell
Slide 7: 1. Financial & Operational Highlights
For personal use only 1. FINANCIAL & OPERATIONAL HIGHLIGHTS
Slide 8: FY25 Financial Summary
FY25 Financial Summary For personal use only Global Sales Australian Sales North American Revenue Revenue Sales Revenue $7.3m $5.3m $2.0m Up 49% Up 40% Up 76% EBITDA (ex-R&D)1 Cash + Term Gross Profit Deposit $(3.1)m Margin $5.9m (excludes $2.1m 65.4% A$2.8m raised from improvement the US placement)
Slide 9: Immuron: integrated biopharmaceutical company with global scale
Immuron Ltd is an Australian integrated biopharmaceutical company with global scale, focused on developing, and commercialising, oral immunotherapeutic for the treatment of gut mediated diseases For personal use only Research & Market Our Footprint: Australia, Canada & US Technology Global Platform
Slide 10: Travelan continued strong sales growth
Travelan® continued strong sales growth Global Year to Date Net Sales ($AUD) Global $8,000,000 For personal use only + FY2025 AUD$7.3 million up 49% on prior year $7,000,000 + FY2026 Q1 AUD$2.0 million up 34% on FY2025 Q1 $6,000,000 $5,000,000 $4,000,000 $3,000,000 $2,000,000 Australia $1,000,000 $-
Slide 11: Expansion of Travelan Distribution
EXPANSION OF TRAVELAN® DISTRIBUTION For personal use only 8
Slide 12: 2. Clinical Development Program
For personal use only 2. CLINICAL DEVELOPMENT PROGRAM
Slide 13: Status of product portfolio and key milestones
Status of product portfolio and key milestones For personal use only Peak U.S. Collaborator or Funding Anticipated Dates Indication Compound Preclinical Phase 1 Phase 2 Phase 3 Registration Current Status sales Source 2H 2025 1H 2026 Uniformed 100% of 851 Traveller's Diarrhoea Travelan® US$ 102 m Se
Slide 14: 3. Upcoming Milestones & Outlook
For personal use only 3. UPCOMING MILESTONES & OUTLOOK
Slide 15: Upcoming Milestones & Outlook
Upcoming Milestones & Outlook Commercial For personal use only + Continued quarter on quarter growth of Travelan® from growth drivers + Planned growth in profitability1 of Hyperimmune products net of planned increased investment in selling & marketing Clinical IMM-124E (Travelan®): Traveller’s Diarr
Slide 16: Scientific references
Scientific references Travelan® (IMM-124E) Travelan® has been shown to reduce both the incidence and severity of ETEC- For personal use only Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: 10.3109/00365521.2011.574726 induced diarrhea in up to 90% of volunteers Clinical Evaluation of
Slide 17: Steven Lydeamore, Chief Executive Officer
For personal use only STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172